Pazib 400MG Tablet, containing the active ingredient Pazopanib at a dosage of 400mg, is a targeted therapy primarily used in the treatment of advanced renal cell carcinoma (kidney cancer) and soft tissue sarcoma. This medication works by inhibiting multiple tyrosine kinases, which are enzymes involved in the signaling pathways that promote tumor growth and angiogenesis (the formation of new blood vessels that supply tumors). By blocking these pathways, Pazib helps to slow down or stop the growth of cancer cells. The tablet is typically prescribed for patients who have not responded to other treatments or for whom other therapies are not suitable. It is essential for patients to follow their healthcare provider’s instructions regarding the use of this medication to achieve optimal results. Pazib is available in a pack of 30 tablets, making it convenient for patients to manage their treatment regimen.

Pazib 200MG Tablet, containing the active ingredient Pazopanib at a dosage of 200mg, is a targeted therapy primarily used in the treatment of advanced renal cell carcinoma (kidney cancer) and soft tissue sarcoma. This medication works by inhibiting multiple receptor tyrosine kinases, which play a crucial role in tumor growth and angiogenesis (the formation of new blood vessels that supply nutrients to tumors). The composition of Pazib includes Pazopanib as the active component, along with various excipients that aid in the tablet’s formulation and absorption. As a part of cancer treatment regimens, Pazib is often prescribed to patients who have not responded to other therapies, providing a vital option in the management of these challenging conditions. Its mechanism of action not only targets cancer cells but also helps in reducing the blood supply to tumors, thereby slowing their growth and spread.